Fig. 1

MASTL is associated with tumor progression in breast cancer. a Representative microscopic images of breast cancer and normal tissue counterparts stained with anti-MASTL antibody (left panels). Scale bars = 500 μm. b, d Quantified staining intensity of MASTL in breast cancers (n = 55) and normal tissues (n = 24). Staining intensity was scored as follows: 0, no staining; + 1, weak; + 2, moderate; and + 3, strong. *P < 0.05 compared with staining intensity of normal tissues. c MASTL mRNA expression in normal and breast cancer tissues was analyzed by using the GENT database (medicalgenome.kribb.re.kr/GENT). e MASTL mRNA expression in different breast cancer grades was analyzed by using the Oncomine database (http://www.oncomine.org) with the Ginestier dataset. The data are presented as box-and-whisker plots b, c, d, e. f MASTL and g PLK1 mRNA expression in breast cancer tissues and their normal counterparts (n = 46). h The cells were analyzed by immunoblotting for anti-MASTL and anti-PLK1 antibodies. The data represent typical results and are presented as the mean ± standard deviation of three independent experiments